Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes

Nigel O'Farrell

Background: The recognition that sexually transmitted infections (STI) facilitate HIV transmission among heterosexuals has led to a rejuvenated focus on improving STI control as a component of HIV prevention programmes in developing countries. While efforts so far have focused mainly on all STI, there is increasing evidence that genital ulcers facilitate a considerable proportion of HIV transmission among heterosexuals and that this effect has been underestimated. This paper focuses on the epidemiology of genital herpes in developing countries past and present.

Objectives: To review the scientific literature about the epidemiology of genital herpes in developing countries and discuss the implications of the findings for STI control and HIV prevention programmes.

Search methodology: A Medline search for June 1966 to August 1999 using the keywords, genital herpes, STD and developing countries, and genital ulcers in MeSH and free text. Abstract books from recent international AIDS conferences and other international STD conferences were reviewed. The annual reports of the medical officers of heath for Harare 1982–1998 and Durban 1989–1997 were reviewed to detect trends in genital herpes diagnoses.

Findings: Genital herpes, formerly regarded as a minor STI in most developing countries, has now emerged as a leading cause of genital ulceration in many countries where syphilis and chancroid were more prevalent previously. This increased recognition of genital herpes reflects both a change in the pattern of STI epidemiology through a decline in syphilis and chancroid as a result of HIV control programmes and improved techniques for diagnosing herpetic infection. Countries with significant heterosexual HIV epidemics also appear to have rapidly increasing numbers of genital herpes cases.

Conclusions: The emergence of this herpes epidemic must be addressed through innovative strategies that will be viable, sustainable, acceptable, and effective in developing countries. In countries where genital herpes is a significant problem, local adaptation of WHO treatment algorithms should be made. STI service providers should be trained about issues around the transmission of herpes and how best to advise clients about dealing with, and recognising, recurrences. The effectiveness of antiviral treatment for genital herpes should be investigated in core groups at high risk of HIV.

Introduction

The role of sexually transmitted infections (STI), and genital ulcer disease (GUD) in particular, in facilitating heterosexual transmission of HIV in developing countries is well established.1 This recognition has led to an increased focus on STI cases to be managed at the primary healthcare level using the syndromic approach. However, although syndromic management was put forward by the World Health Organisation as a strategy for limiting the morbidity of sexually transmitted diseases in developing countries in the early 1980s before HIV became a significant problem, it is clear that further innovative strategies are needed to reduce the global burden of STI.

Numerous studies have identified higher relative risks of HIV infection with GUD than with other STI and STI syndromes.2 This risk differential depends upon both the relative frequencies of the various STI syndromes in different populations and the direction of HIV transmission—that is, male to female or female to male.3 Population attributable risks of HIV to GUD as high as 69% among male clients of female sex workers (FSW) in Nairobi4 (relative risk (RR) 11.3) and 54% in STI clinic attenders in India5 (RR 7.0) are reported. At the individual level, an assessment of the GUD cofactor effect per sexual exposure of HIV transmission determined an increased risk of 10–50 for male to female and 50–300 for female to male.6

Most STI strategies and programmes have tended to target STIs overall and have not taken into account the diverse prevalences of the various STI syndromes that occur in different geographical locations. In most countries of east, central, and southern Africa, a much higher incidence of genital ulceration is reported than in west Africa. A similar epidemiological pattern is seen in the spread of HIV
HSV transmission has been underestimated in part that asymptomatic viral shedding plays in example, mild episodes of genital herpes. The asymptomatic ulcers as an STI problem—for microbiological surveys for this reason. are therefore also likely to be underrepresented uncommon—none of the Durban patients had tion with typical herpetic vesicles may be resolved in the first week or so. Also, presenta- settings because signs and symptoms will have genital herpes will not present to healthcare common, it is likely that many patients with HSV in microbiological studies alone. Also, it may be that the low reported prevalence of HSV in microbiological studies in Africa reflects the order in which swabs were taken from ulcers. Swabs are usually taken in the order of the most likely clinical diagnosis to maximise positive diagnoses. If HSV was thought to be uncommon, swabs for H ducreyi and syphilis would be taken first followed by those for HSV. The likelihood of obtaining material from ulcers that would grow herpes simplex by the time a third swab was taken would be expected to be low. (3) Unrecognised complications of GUD—for example, healed ulcers, may cause tissue contraction and thinning of genital mucosa, particularly in uncircumcised men, which may be susceptible to tears and abrasions if subjected to trauma, and thereby facilitate acquisition of HIV. These complications may not be attributed to an episode of genital ulceration. (4) Delay in presentation with GUD to a healthcare facility. For example, among STD clinic attenders with GUD in Durban, 34% of men and 36% of women delayed for >14 days after the start of ulcer symptoms before presentation and 9% of the men and 13% of the women delayed for more than 30 days. In patient groups where delayed presentation is common, it is likely that many patients with genital herpes will not present to healthcare settings because signs and symptoms will have resolved in the first week or so. Also, presenta- tion with typical herpetic vesicles may be uncommon—none of the Durban patients had herpetic vesicles. Patients with genital herpes are therefore also likely to be underrepresented in microbiological surveys for this reason. (5) Lack of recognition of small and/or asymptomatic ulcers as an STI problem—for example, mild episodes of genital herpes. The part that asymptomatic viral shedding plays in HSV transmission has been underestimated in the past. At the population level, the risk of HIV transmission attributable to HSV through asymptomatic shedding could be very significant. (6) Other factors that could reflect an underestimation of the true effect of GUD on HIV transmission also apply to STIs in general and include: (a) underestimation of self reported STI in STI clinic populations—patients may not report previous STI because of stigma or, in repeat attenders, a fear of derogatory comments from healthcare providers who have advised them previously about safer sex; (b) lack of temporal sequence of disease acquisition—in cross sectional studies, subjects identified with genital ulcers and in the process of HIV seroconversion may be in the HIV window period at the time of testing. All of these points are relevant to genital herpes and explain why the condition has been underestimated. Despite its recognition as a possible risk factor for HIV infection in heterosexual populations at high risk of HIV in sub-Saharan Africa some time ago, herpes is only now starting to receive more attention in developing countries because of its possible importance in facilitating HIV transmission.
Although diagnostic facilities for herpes have not been available routinely, some health departments have kept a separate tally of cases of genital herpes based on clinical diagnoses. Among STI attenders at three municipal clinics in Harare, Zimbabwe, genital herpes accounted for 6.1% of all STI cases in 1982. When genital herpes was introduced into routine reporting at the city health STI clinic in Durban in 1989, 2806 cases were diagnosed whereas, previously, genital herpes was classified under non-STIs. Although HIV related immunodeficiency may be a factor in HSV recurrences, the prevalence of HIV in both Harare and Durban at these times was low.

Results from the limited numbers of studies undertaking HSV-2 serology indicate significant prevalences among sexually active individuals in diverse locations—96% in sex workers in Dakar, Senegal (1985), 71% in adults in Brazzaville, Congo (1982), 51% in hospital workers in Rwanda (1985), and 41% in adults in Kinshasa, Zaire (1985). Although these studies used older serological tests, which are recognised as having limited diagnostic value because of their lack of sensitivity, these levels are comparable with, if not higher than, similar prevalences in developing countries throughout the world.

A notable pointer to the underdiagnosis of HSV in Africa is perhaps reflected in the study by Hazlett et al. who showed that even in the early 1980s, 13% of men with genital ulcers with clinical appearances diagnostic of chancroid had proved genital herpes.

**HSV in developing countries: the present**

The spread of HIV since the 1980s and subsequent behaviour change have resulted in significant alterations in STI epidemiological patterns in which the relative importance of genital herpes has increased in many countries. In Asia, these changes may reflect increased condom use and a reduction in sexual contact with sex workers. The most noticeable example of this phenomenon has been in Thailand where the incidence of chancroid and syphilis was reduced from nearly 39,000 and 11,855 cases in 1987 to 1990 and 3645 respectively in 1993. In Singapore, genital herpes (72%) is now by far the most common cause of GUD followed by chancroid (16%) and syphilis (3%). In Kuala Lumpur, Malaysia, HSV-2 was identified by culture and immunofluorescence in 19% and H ducreyi in 9% of STI clinic attenders with GUD. A survey of five STD clinics in Papua New Guinea identified genital herpes, diagnosed clinically, as the most common cause of GUD.

Changes in the epidemiological patterns of GUD have been less pronounced in Africa compared with Asia. In Africa, condom use is still very low in many countries and commercial sex encounters may not be as readily identified as high risk situations for HIV transmission compared with Asia. However, like Asia, many areas in Africa have shown increasing prevalences of genital herpes. This may reflect not only a global increase in the numbers of cases but also a greater number of HIV positive people in populations sampled. In a population of HIV positive Africans living in London followed up for a mean of 14 months, 42% developed genital herpetic lesions.

The first microbiological study in which a significant prevalence of HSV was detected in Africa was in Rwanda where prevalences of 18% in men and 20% in women were detected by culture among patients with GUD of whom 43% of the men and 77% of the women were HIV positive. Studies elsewhere using viral culture, in men and women, detected HSV prevalences of 48% in Kampala, Uganda (65% HIV positive) and 24% in Botswana (41% HIV positive). There are few reliable data about trends in chancroid infections in Africa although in Zimbabwe, one of the worst affected countries with HIV, the numbers of cases diagnosed clinically at the genitourinary centre in Harare decreased from 2972 in 1990 to 430 in 1998. While this decrease is not as dramatic as in Thailand, these data suggest that STI interventions are achieving a significant impact although any clinical reports of disease specific diagnoses in Africa must be viewed with caution.

Increased access and availability of HSV-2 antibody tests have confirmed significant prevalences of HSV infection in Africa. In rural populations in Africa sampled randomly, the prevalence of HSV-2 antibodies was 75% in women >25 years and 60% in men >30 years in Mwanza, Tanzania and 68% overall in Masaka, Uganda. High rates (59%) are also reported in commercial sex workers in Nigeria. Among young men recruited into the armed forces in northern Thailand, the HSV-2 antibody prevalence was 41%. These levels are higher than those in the United States, where, since the 1970s, the prevalence of HSV-2 in the general population increased by 30% to levels of 26% in women and 18% in men in 1988–94.

Genital herpes is also a significant problem in central and South America. HSV-2 type specific antibodies were detected in 61% of commercial sex workers in Mexico City, 53% of STI patients in Campinas City, Brazil, and 39% of women selected randomly in Costa Rica.

**TESTING WITH MULTIPLEX PCR**

An important development in the 1990s has been the introduction of a multiplex polymerase chain reaction (PCR) assay for genital ulcers. This has enabled an assessment to be made for genital herpes in situations that do not have routine access to viral culture. Results from these studies are shown in table 1 and demonstrate significant prevalences of genital herpes in all the populations studied. The highest prevalence was reported in STI clinic attenders with genital ulcers in northern Thailand where 31/38 (82%) were positive for HSV from a population in whom 46% were HIV positive. In Pune, India, genital herpes was the most frequent infection (26%) followed by chancroid (16%) and syphilis (10%). In Africa, 43% of subjects with genital ulcers in the Rakai mass treatment trial and 26% in...
Table 1: Genital herpes and HIV status in subjects with genital ulcers using a multiplex polymerase chain reaction (M-PCR) assay

<table>
<thead>
<tr>
<th>Study subjects</th>
<th>HSV (%)</th>
<th>HIV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maseru, Lesotho</td>
<td>69 male STI, 36 female STI</td>
<td>26</td>
</tr>
<tr>
<td>Rakai, Uganda</td>
<td>207 men and women</td>
<td>43</td>
</tr>
<tr>
<td>Carletonville, South Africa</td>
<td>213 male and female STI</td>
<td>13</td>
</tr>
<tr>
<td>Capetown, South Africa</td>
<td>213 male and female STI</td>
<td>22</td>
</tr>
<tr>
<td>Abidjan, Ivory Coast</td>
<td>94 female sex workers</td>
<td>27</td>
</tr>
<tr>
<td>Asia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pune, India</td>
<td>277 male STI, 25 female STI</td>
<td>26</td>
</tr>
<tr>
<td>Chiang Mai, Thailand</td>
<td>8 male STI, 30 female sex workers</td>
<td>82</td>
</tr>
<tr>
<td>Phonm Penh, Cambodia</td>
<td>17 female sex workers/men</td>
<td>79</td>
</tr>
<tr>
<td>Caribbean</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kingston, Jamaica</td>
<td>252 male STI, 52 female STI</td>
<td>52</td>
</tr>
</tbody>
</table>

NG = not given.

Masaru, Lesotho, were identified with genital herpes. Finally, it was thought that, with the introduction of PCR, the numbers of cases with no known cause, previously around 20–30% in most studies, would be low. However, while the proportion of unidentified ulcers was only 6% in Lesotho, no cause was identified for 51% in Rakai, Uganda. Rompalo and colleagues have discussed different definitions for genital ulcers and found that different communities have different perceptions about the significance of genital ulcers.

HSV AS A RISK FACTOR FOR HIV
As tests for herpes have become more widely available, so the evidence implicating HSV in HIV transmission has increased and has been discussed in recent review articles. More recent studies have added further evidence supporting the association between HSV-2 antibodies and HIV. Significant correlations between HIV and HSV-2 specific antibodies were found in Zimbabwe among male factory workers (odds ratio (OR) 8.0), in Tanzanian STI clinic attenders (OR 2.5), and in Thai military recruits with a history of ulcers in the past 3 years (prevalence ratio (PR) 14.4) and in those without a history of ulcers (PR 2.6), and in STI patients in Lesotho (PR 1.9). In the population based study in Masaka, Uganda, the initial phase showed high levels of HSV seropositivity—57% in men and 74% in women but an OR for association with HIV infection of only 1.2. However, in a later phase of the study the RR of HSV incidence was 3.7 in HIV positive cases versus HIV negative and HIV prevalence was strongly associated with HSV-2. While this study did not examine the relation between HIV incidence and HSV-2 incidence, the population risk of HIV attributable to genital herpes is likely to be considerable given that recurrent episodes of genital ulceration are common.

Trends in HSV
Until recently most diagnoses of herpes in developing countries were made on clinical grounds and were therefore open to observer error. However, in areas where longitudinal data are available, a steady rise in the number of genital herpes cases has been recorded. In Singapore, genital herpes cases increased threefold among STI clinic attenders between 1977 and 1993. In Chandigarh, India, a fourfold increase in genital herpes was observed in STD clinic attenders from 1977 to 1990. In Harare, genital herpes diagnosed clinically increased from 6.1% of all new STI diagnoses in 1982 to 462/4822 (9.6%) in 1993 and 736/7167 (10.3%) in 1997. In Durban, clinical genital herpes cases/new STI diagnoses increased from 2806/41 126 (6.8%) in 1989 to 5664/53 057 (10.7%) in 1994, and to 7865/72 363 (10.9%) in 1997. A more dramatic increase can be observed in the increased prevalence of HSV detected by culture in men with GUD in Durban from 7% in 1984 to 10% in 1989 and 40% in 1998. It is not known whether these raised HSV rates are just in HIV positive cases or also in HIV negative cases (which might imply an overall increase in HSV transmission secondary to the HIV epidemic). The overall prevalence of HSV in the Durban/KwaZulu/Natal region increased from <1% in 1989 to 32.5% in 1998.

Elsewhere in South Africa, a significant increase in the prevalence of genital herpes from 3.3% to 14.4% was observed over three cross sectional studies involving 200 patients with genital ulcers per round in 1986, 1990, and 1994 in a population of gold miners in Johannesburg. During the same time the prevalence of HIV in patients with ulcers increased from <1% to >40%. In Rwanda the prevalence of culture confirmed HSV in HIV positive patients with GUD increased from 11% in 1986–8 to 21% in 1990–92.

In Nigeria, the prevalence of HSV-2 antibodies in female sex workers ranged from 25% in 1978 in Ibadan to 59% in Lagos in 1990/1. In Kinshasa, Zaire, the prevalence of HSV antibodies in selected comparable populations increased from 21% to 60% between 1959 and 1985 and in rural areas from 6% to 32%. An exception to this trend of increasing HSV infection was reported in Jamaica where a decrease in the prevalence of genital herpes over time from 17% in 1982/3 to 7% in 1990/1 was thought to reflect intense media coverage for genital herpes in 1982/3. However, by 1996, genital herpes, detected by PCR, accounted for 52% of GUD among STI patients in Kingston.

These studies indicate a significant increasing prevalence of HSV-2 throughout the developing world. It would seem that most countries with high prevalences of HIV also have a considerable public health problem with genital herpes.

Implications of emergence of HSV SYNDROMIC MANAGEMENT
In 1985, WHO guidelines set out a simplified genital ulcer protocol that recommended treating ulcerative lesions for syphilis and chancroid and managing multiple superficial lesions with vesicles as genital herpes. The 1991 protocol also recommended that vesicular lesions or a history of vesicles should be managed as herpes and other ulcers be treated for syphilis or chancroid. Evaluations of this protocol for correct treatment of syphilis and chancroid in Kigali, Rwanda, found a sensitivity of 99%.
Increasing prevalence of genital herpes in developing countries

However, the sensitivity for genital herpes using diagnostic criteria vesicles or a history of vesicles was only 5% compared with 48% for clinical diagnosis. The WHO recommendations for GUD published in 1994 advised treatment for syphilis and chancroid but did not include herpes management in the algorithm although it was acknowledged that an increasing proportion of ulcers were likely to be herpetic where HIV infection was prevalent.77 Recently a WHO advisory group has recognised the importance of genital herpes and recommended that subjects with vesicles or small ulcers, with a history of recurrent vesicles, should be managed as if they had genital herpes.78

In many areas where genital herpes is now the most frequent cause of GUD, WHO guidelines for GUD have not been accepted. Physicians proud of their clinical acumen are loath to treat for syphilis and chancroid when herpes presents with classic appearances. Similarly, other STI service providers may be unwilling to give scarce antibacterial drugs for those with a high probability of being infected with herpes rather than syphilis and/or chancroid.

An evaluation of the 1994 WHO algorithm for GUD in a population with significant prevalences of chancroid, syphilis, and genital herpes showed a 63% overtreatment for syphilis and no patients receiving adequate herpes counselling, clearly an unsatisfactory outcome.79 The performance of the GUD algorithm improved with the criteria of small blisters, small ulcers, and a history of recent blisters for a diagnosis of herpes, so that counselling was adequate in 29% of genital herpes and, although overtreatment for primary syphilis was 57%, correct treatment for other causes of GUD was still 90%.

If genital herpes have recurrences, they may assume that further treatment is indicated based on their experience of receiving an injection and a course of antibiotics at their previous attendance if managed under the 1994 protocol. This message will then be reinforced again repeatedly at subsequent visits. Whether this strategy is effective at the community level is unknown. While cases of syphilis and chancroid will receive effective treatment, the incidence of repeat syphilis and chancroid infections will be very low compared with the numbers of herpes recurrences. Also, if patients do not comply with extended courses of erythromycin, the usual drug of choice for chancroid, and yet still find that their ulcer is cured, they may lose faith in the STD service offered. Unnecessary overtreatment could alter treatment seeking behaviour at the community level leading to subsequent delays in presentation of syphilis and chancroid.

Parallels can be drawn with the WHO algorithm for vaginal discharge used as a predictor of cervical infection with gonorrhoea or chlamydia in which positive predictive values as low as 10% are difficult to justify on economic grounds.80 In those countries where drug expenditure for a single STI syndrome is more than the average healthcare expenditure per annum and drugs are continually in short supply, healthcare workers will be reluctant to overprescribe to the extent required for the current syndromic management approach guidelines to be a successful strategy alone.

A further problematic area in syndromic management of GUD is partner notification. Patients treated for GUD are usually advised that their partners should attend and receive epidemiological treatment. This may be a source of discontent and friction in couples who may assume that their partner has had other sexual partners outside the relationship. Issues about partner notification for contacts of index cases with genital herpes are still uncertain, particularly in areas where multiple causes of GUD are prevalent. Although many patients are infected by asymptomatic partners some of these supposedly asymptomatic infected subjects can be taught to recognise signs and symptoms of genital herpes that have gone unrecognised previously.81 While discussion of genital herpes transmission with partners may not be straightforward, the consultation would, at the very least, provide an opportunity both for health education and to reinforce the importance of abstaining from sexual intercourse while genital ulcers are present.

Previous WHO treatment guidelines have not taken into account regional variation in GUD epidemiology. While the WHO algorithm has been demonstrated to be cost effective in Rwanda,76 in countries with established high prevalences of HSV approaching levels in the west—for example, Thailand, there is a clear justification for genital ulcer algorithms to include genital herpes. Some Asian countries have acknowledged this and made their own adaptations—for example, in the Philippines, where syphilis and chancroid are very uncommon causes of GUD, all GUD cases are managed as probable genital herpes.82 In Cambodia, guidelines also have specific recommendations for probable herpes cases assessed on a clinical basis.83 Clearly, issues around overtreatment of STI and GUD as part of the syndromic approach in countries with scarce resources present a dilemma. Although overtreatment is acknowledged and unavoidable in syndromic management, the numbers of cases that receive unnecessary treatment which is acceptable to budget holders merit closer economic scrutiny.

Further adjustment of GUD algorithms will need to be made in areas with a high prevalence of HIV where delayed healing of ulcers is likely to become an increasing problem. While most cases of GUD caused by syphilis and chancroid usually respond to recommended treatments as anticipated, genital herpes has been identified as both the main cause of treatment failure in Malawi84 and the likely cause of increased ulcer severity and chronicity seen in HIV positive patients compared with HIV negative patients in Nairobi.85

Ideally, every country with significant GUD prevalences should develop and evaluate its own algorithms under local conditions. Up until now, guidelines have drawn up with an emphasis on simplicity so that one universal algorithm can cover one STI syndrome.
Although policymakers have seemed reluctant to involve those actually involved in STI case management, it is clear that local experts must be consulted so that adaptations can be made which are suitable for use at the country, or even the provincial, level.

COUNSELLING

Although the WHO recommends that STI case management be provided at the primary healthcare level there are many obstacles in implementing this policy. In the absence of affordable antiviral therapy for HSV, if STIs and genital herpes to be dealt with adequately at the primary healthcare level, the issue of acquiring health education and counselling skills must be addressed in training workshops for STI service providers. The content of the training curriculum will require consideration of the many myths that have grown up around herpes and how they are perceived in communities. Where STIs are seen as a curse or punishment, providing a plausible explanation for an STI liable to recur and for which treatment is not available will be difficult. Issues over herpes transmission and the likelihood of recurrences are still surrounded by uncertainty, as are the best ways of discussing these points with patients. However, given the potential importance of HSV in facilitating HIV transmission, guidelines that could be used in a variety of settings must be drawn up and evaluated as a priority. The new WHO recommendations are awaited keenly particularly if they can be adapted readily for use in countries with significant numbers of cases, know their patient group, and are experienced in how best to reassure clients. They will also be able to explain how the problem can best be dealt with in a sensitive, non-judgmental manner appropriate to the particular culture of the individual.

Counselling about HSV should also be viewed as an opportunity to discuss HIV and HIV testing. Patients with HSV are at increased risk of HIV and in many cases may be HIV infected already. As voluntary testing and counselling become more acceptable in communities, there is a real potential for skills learnt in counselling for HSV to be applied for HIV and vice versa.

Counselling and health education for HSV are likely to be the most effective options in the management of HSV for some time. Although the cost of aciclovir has reduced considerably in developed countries, pricing in developing country settings remains prohibitively high. To have a significant impact on the prevalence of HSV-2, aciclovir use would have to be widespread and sustained. If the cost of aciclovir were to be reduced further, its use should perhaps be considered in core groups at high risk for HIV infection but not as a substitute for condoms. Donors should be lobbied about providing funds so that, at the very least, those with genital herpes lesions as a consequence of advanced immunodeficiency can have access to anti-herpes medication.

Conclusions

HSV appears to be increasing significantly in developing countries. This has important implications for the spread of HIV because of the facilitatory effect of GUD on HIV transmission.

Algorithms for GUD have changed little over the years since the HIV epidemic became established and must take into account the increased prevalence of HSV now and the likelihood that it will increase in the future. In countries where syphilis and chancroid are still prevalent, it would still be reasonable to treat all new cases of genital ulceration for syphilis and chancroid. Those with recurrences should be interviewed and asked about previous episodes of ulceration typical of herpes. Such cases would not be treated for syphilis and chancroid but would be counselled about herpes and asked to return.

The increasing incidence of genital herpes is part of a rapidly changing profile of STI epidemiology in developing countries. Putting STI surveillance systems in place will be crucial in monitoring such changes so that appropriate adjustments can be made to treatment schedules to make them more cost effective. Strong consideration should be given to supporting STI surveillance for GUD in areas with high prevalences of HIV. While this support has been sadly neglected in the past, policymakers now need to be targeted so that further opportunities to limit the spread of HIV, in particular by decreasing the incidence of GUD and genital herpes, are not missed.


87 White PJ, Garnett GP. Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2. Sex Transm Inf 1999;75:49–54.